SCHEMBL143786

SCHEMBL143786

COC(=O)c1cc(-c2ccc(OC)c(F)c2)nc2c3ccc(N4CCCN(C)CC4)cc3n(Cc3ccc(OC)cc3)c12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 3/20 0.52
FGFR1 P11362 2/20 0.39
FGFR2 P21802 1/20 0.39
MEN1 O00255 1/20 0.37
HPGD P15428 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
F10 P00742 10/20 0.37
BRD4 O60885 1/20 0.37
USP2 O75604 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
GLA P06280 1/20 0.36
CYP3A4 P08684 1/20 0.36
TSHR P16473 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
HIF1A Q16665 1/20 0.36
LCK P06239 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL141523 0.84 PLA2G2A (0.47) JAK2MEN1KMT2AALDH1A1CYP1A2
SCHEMBL141898 0.79 JAK2 (0.80) JAK2FGFR1FGFR2BRD4LCK
SCHEMBL144258 0.78 HDAC1 (0.37) JAK2HPGDALDH1A1GLACASP1
SCHEMBL144259 0.78 JAK2 (0.42) JAK2ALDH1A1PLA2G2A
SCHEMBL110326 0.78 P2RX3 (0.40) JAK2SMN1; SMN2L3MBTL1ALDH1A1PLA2G2A
SCHEMBL170380 0.76 PDE1B (0.41) JAK2FGFR2
SCHEMBL141484 0.73 JAK2 (0.94) JAK2
SCHEMBL139706 0.72 JAK2 (0.38) JAK2MEN1HPGDKMT2ASMN1; SMN2
SCHEMBL142075 0.71 PLA2G2A (0.46) JAK2MEN1HPGDKMT2AALDH1A1
SCHEMBL143205 0.71 PLA2G2A (0.49) MEN1HPGDKMT2AALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 JAK2 1/4885FGFR1 420/4885FGFR2 572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.